Elon Musk says he prefers Lilly’s Mounjaro over Novo’s Ozempic
CEO's use of Eli Lilly's (LLY) weight loss drug Mounjaro over Novo Nordisk's (NVO) rival product, Ozempic. Read more here.
24/7 Wall St3h
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 501.82% and ...
24/7 Wall St2h
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Weight Loss Drug Mounjaro to Be Launched in India in 2025; Know How It Tackles Obesity
Global pharma giant Eli Lilly plans to launch its diabetes and obesity treatment, tirzepatide, marketed under the brands ...
2025 Analyst Outlook: Edmund Ingham On Biotech Big And Small, And A Key Milestone
Lower interest rates boost biotech investments by increasing risk appetite, benefiting pre-commercial biotechs. Read more on how these companies may perform in 2025.
Jim Cramer Says Eli Lilly and Company (LLY)’s ‘Going To Win’
We recently compiled a list of the Jim Cramer Discusses 17 Stocks And Blasts Zero Day Options. In this article, we are going ...
Alaska Dispatch News18hOpinion
Opinion: We’ve accepted Wegovy and Zepbound. The next phase is harder.
An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...
FDA approves first medication for obstructive sleep apnea — which also promotes weight loss
The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).
Why some children are turning to GLP-1 weight loss drugs
A growing number of young people are receiving prescriptions for GLP-1 weight loss medications like Ozempic and Wegovy. Janet ...